Spots Global Cancer Trial Database for allogeneic hsct
Every month we try and update this database with for allogeneic hsct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | NCT04179929 | Acute Lymphobla... | Pediatric-type ... allogeneic HSCT | 18 Years - 60 Years | PETHEMA Foundation | |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | NCT00568633 | Leukemia, Myelo... Leukemia Acute Myeloid L... | Allogeneic HSCT Anti-thymocyte ... Cyclosporine (C... Mycophenolate m... Total lymphoid ... Methylprednisol... Best standard c... | 50 Years - 75 Years | Stanford University | |
| A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT | NCT00477542 | Hematologic Mal... | clofarabine | 18 Years - 60 Years | Indiana University | |
| Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ | NCT02936089 | Acute Myeloid L... Risk Stratifica... | Consolidation w... Consolidation w... allogeneic HSCT | 14 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies | NCT04547049 | Leukemia | Cytarabine Busulfan Cyclophosphamid... Me-CCNU Rabbit antithym... Allogeneic HSCT Cyclosporin A Mycophenolate M... MTX | 14 Years - 60 Years | First Affiliated Hospital of Zhejiang University | |
| Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | NCT04179929 | Acute Lymphobla... | Pediatric-type ... allogeneic HSCT | 18 Years - 60 Years | PETHEMA Foundation | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies | NCT04547049 | Leukemia | Cytarabine Busulfan Cyclophosphamid... Me-CCNU Rabbit antithym... Allogeneic HSCT Cyclosporin A Mycophenolate M... MTX | 14 Years - 60 Years | First Affiliated Hospital of Zhejiang University | |
| Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+ | NCT02936089 | Acute Myeloid L... Risk Stratifica... | Consolidation w... Consolidation w... allogeneic HSCT | 14 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | NCT00568633 | Leukemia, Myelo... Leukemia Acute Myeloid L... | Allogeneic HSCT Anti-thymocyte ... Cyclosporine (C... Mycophenolate m... Total lymphoid ... Methylprednisol... Best standard c... | 50 Years - 75 Years | Stanford University | |
| Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS | NCT01540812 | Acute Lymphobla... | Vincristine in ... Daunorubicin in... Prednisone in i... Metotrexato in ... Cytarabine in i... Hydrocortisone ... Idarubicin in i... Fludarabine in ... Ara-C in induct... G-CSF in induct... Dexamethasone i... Vincristrine in... Metotrexato in ... PEG-ASP in cons... Dexamethasone i... ARA-C in consol... PEG-ASP in cons... Dexamethasone i... Vincristine in ... Metotrexato in ... PEG-ASP in cons... allogeneic HSCT Allo HSCT with ... | 15 Years - 60 Years | PETHEMA Foundation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
